Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
about
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob miceIncretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsThe class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitusA nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.A model of GLP-1 action on insulin secretion in nondiabetic subjects.Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects.Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled studyGIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetesPatient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathwayExogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.Review: Placental programming of postnatal diabetes and impaired insulin action after IUGR.Model-Based Quantification of Glucagon-Like Peptide-1-Induced Potentiation of Insulin Secretion in Response to a Mixed Meal Challenge.Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.Nutrigenomics--2006 update.Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine.Orlistat in the prevention of diabetes in the obese patientUpdate: vildagliptin for the treatment of Type 2 diabetes.Opportunities for the replacement of animals in the study of nausea and vomitingLong-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept.Waking up the gut in critically ill patients.Immortalized neurons for the study of hypothalamic function.Fructus Gardenia (Gardenia jasminoides J. Ellis) phytochemistry, pharmacology of cardiovascular, and safety with the perspective of new drugs development.Gastrointestinal hormones and polycystic ovary syndrome.Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure.Paralog-divergent Features May Help Reduce Off-target Effects of Drugs: Hints from Glucagon Subfamily Analysis.Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.To be or not to be--an incretin or enterogastrone?Neuroprotective effects of liraglutide for stroke model of rats.Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction.Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?Effect of glycosylation on biodistribution of radiolabeled glucagon-like peptide 1.Physiological mechanisms for the increase in renal solute-free water clearance by a glucagon-like peptide-1 mimetic.Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
P2860
Q24629441-1549F10D-A73F-4636-BA2C-1F60645FBCE1Q26778608-ADACBBA7-7901-43D0-819F-1C696245C438Q26828940-B09FC24A-EEE7-4EE4-BFA1-6E013504E153Q33268721-1DD1FA70-FB5D-49B3-A496-BDE7C1A82A82Q33570118-D4E84FB4-0C3C-47D8-BB6C-E8E6208D9D9CQ33916585-8524D0C6-16EC-4201-BF44-5730004DDB75Q34016159-06BA0768-DCD9-4C4E-9B12-195E9E0A548DQ34068749-6C8A9BEC-3798-4083-BA60-5811AE5663ACQ34167798-9D41914D-ACD5-45E8-9262-77735A05F873Q34718860-DB63B3E6-D39C-4A0A-890F-C33E731FE2ADQ35126645-7F293129-A381-4CE7-AB9B-D7E2E05FF7BAQ35134808-ADCF3195-6D02-4B8F-8180-252ED6979833Q35567284-C4368E15-54C3-438C-9C36-CA61B68D3148Q35800392-CF572F2F-6220-4C2E-9533-3C88A43574BEQ35810917-645E0D3D-A739-4B23-A673-C377BE1D3CACQ36475938-0703506B-0F69-4065-8F40-E78739EF3311Q36593147-55EE2ADA-EAEE-4AC9-A935-0F743F72E0D6Q36766848-8C721AF5-3EC3-49D8-A3C7-0280A011533BQ36772839-89A1EE74-1F10-4827-B72B-C1F5288922B5Q36812759-86AC323F-1D3A-456C-B9F2-EFABAAF4DD05Q37039013-8067E74E-6921-4E3C-88A8-6738193E4EF4Q37332618-B47CCFD6-B787-49E2-B13F-C33E3DAB7D42Q37381194-13514307-B63E-43DA-83C0-F55CE2133BB1Q37795946-4AC8E395-6635-4FD6-80B6-0DA250485306Q37830228-6A9ADE16-1C80-4DAC-AEBA-4C1024D81326Q38064967-E0D69C0A-1A2E-4306-B9C4-FA585B61059AQ38208929-2DA36879-8162-4561-A8F9-199B27FF2E57Q38213037-3308AA44-FE62-4FE0-BDA8-4C55C5CB3CDDQ38713210-DD15550D-44BA-4DC0-8472-BF1750ADF1D4Q41267217-BDD27342-F651-432D-975B-538E48DFE681Q41883921-B58194BE-CCA8-45AC-A50C-BC187FB99959Q42078124-40523F88-6057-4181-B8A4-FD293617C379Q42675447-E5FE9877-F76D-414E-AC75-EFADFD6DE6C1Q42704044-61DEA66D-A08E-4A9B-8E12-7E25C38B801AQ43225003-B9F49840-1FA9-4A80-A117-17A5FA492D24Q45742352-A2691991-A792-4DBC-B11F-25B7B20912F6Q46922700-DB3767DD-A929-40BE-BBB9-27D7CDA763F8Q50974989-76954EAC-7140-4329-95F0-9C48E2BC1690Q51424631-42935AAE-3B50-4A4A-8B8C-493DE3D7345E
P2860
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
@ast
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
@en
type
label
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
@ast
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
@en
prefLabel
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
@ast
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
@en
P1433
P1476
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
@en
P2093
Juris J Meier
Michael A Nauck
P304
P356
10.1016/J.REGPEP.2004.07.014
P577
2005-06-01T00:00:00Z